Literature DB >> 7836911

Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction.

D Gu1, L Wogensen, N A Calcutt, C Xia, S Zhu, J P Merlie, H S Fox, J Lindstrom, H C Powell, N Sarvetnick.   

Abstract

Abnormal humoral responses toward motor end plate constituents in muscle induce myasthenia gravis (MG). To study the etiology of this disease, and whether it could be induced by host defense molecules, we examined the consequences of interferon (IFN) gamma production within the neuromuscular junction of transgenic mice. The transgenic mice exhibited gradually increasing muscular weakness, flaccid paralysis, and functional disruption of the neuromuscular junction that was reversed after administration of an inhibitor of acetylcholinesterase, features which are strikingly similar to human MG. Furthermore, histological examination revealed infiltration of mononuclear cells and autoantibody deposition at motor end plates. Immunoprecipitation analysis indicated that a previously unidentified 87-kD target antigen was recognized by sera from transgenic mice and also by sera from the majority of human MG patients studied. These results suggest that expression of IFN-gamma at motor end plates provokes an autoimmune humoral response, similar to human MG, thus linking the expression of this factor with development of this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836911      PMCID: PMC2191877          DOI: 10.1084/jem.181.2.547

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

1.  Immunological heterogeneity and cellular mechanisms in myasthenia gravis.

Authors:  J Newsom-Davis; N Willcox; M Schluep; G Harcourt; A Vincent; S Mossman; D Wray; J Burges
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

Review 2.  The biology of myasthenia gravis.

Authors:  D B Drachman
Journal:  Annu Rev Neurosci       Date:  1981       Impact factor: 12.449

3.  Attempts to implicate viruses in myasthenia gravis.

Authors:  T Aoki; D B Drachman; D M Asher; C J Gibbs; S Bahmanyar; J S Wolinsky
Journal:  Neurology       Date:  1985-02       Impact factor: 9.910

4.  Factors affecting the susceptibility of different strains of mice to experimental myasthenia gravis.

Authors:  P W Berman; J Patrick; S Heinemann; F G Klier; J H Steinbach
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value.

Authors:  J M Lindstrom; M E Seybold; V A Lennon; S Whittingham; D D Duane
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

6.  Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

7.  Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity.

Authors:  G F Bottazzo; R Pujol-Borrell; T Hanafusa; M Feldmann
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

8.  Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.

Authors:  S Mossman; A Vincent; J Newsom-Davis
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

9.  Nerve stimulation test in murine experimental autoimmune myasthenia gravis.

Authors:  A R Pachner; F S Kantor
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

10.  Experimental myasthenia gravis. A murine system.

Authors:  P W Berman; J Patrick
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

View more
  22 in total

1.  T cell-independent rescue of B lymphocytes from peripheral immune tolerance.

Authors:  V Kouskoff; G Lacaud; D Nemazee
Journal:  Science       Date:  2000-03-31       Impact factor: 47.728

2.  Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen.

Authors:  M Bakhiet; L-Y Yu; V Ozenci; A Khan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 3.  Current and future therapies for myasthenia gravis.

Authors:  Q Yi; A K Lefvert
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

4.  Lipopeptides of Borrelia burgdorferi outer surface proteins induce Th1 phenotype development in alphabeta T-cell receptor transgenic mice.

Authors:  C Infante-Duarte; T Kamradt
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

5.  Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.

Authors:  Xiuhua Yao; Qingfei Kong; Xiaoli Xie; Jinghua Wang; Na Li; Yumei Liu; Bo Sun; Ying Li; Guangyou Wang; Wenjin Li; Siying Qu; Haijun Zhao; Dandan Wang; Xijun Liu; Yao Zhang; Lili Mu; Hulun Li
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 6.  Viruses, cytokines, antigens, and autoimmunity.

Authors:  R Gianani; N Sarvetnick
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 7.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

8.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.

Authors:  F Baggi; F Andreetta; E Caspani; M Milani; R Longhi; R Mantegazza; F Cornelio; C Antozzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

9.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  CCR2-64I and CCR5Delta32 Polymorphisms in Korean Patients with Myasthenia Gravis.

Authors:  Hyun Sook Kim; Dae-Seong Kim; Eun Young Lee; Il-Nam Sunwoo; Young-Chul Choi
Journal:  J Clin Neurol       Date:  2007-09-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.